

CLINICAL CANCER RESEARCH

TABLE OF CONTENTS

HIGHLIGHTS

6279 Selected Articles from This Issue

SPECIAL FEATURES

CCR Translations

6281 Exploring New Approaches for Locally Advanced Gastroesophageal Adenocarcinomas: TNT, Irinotecan, and ctDNA

Daniel V.T. Catenacci

See related article, p. 6343

6284 Location Matters: Profiling Diffuse Type Gastric Cancer At the Single-Cell Level

Huocong Huang and Rolf A. Brekken

See related article, p. 6529

Reviews

6287 Immunotherapy in Pancreatic Adenocarcinoma: Beyond “Copy/Paste”

Robert Hester, Pawel K. Mazur, and Florencia McAllister

6298 Overcoming Intrinsic Resistance of Cancer Cells to CAR T-Cell Killing

Jean Lemoine, Marco Ruella, and Roch Houot

RESEARCH BRIEFS: CLINICAL TRIAL BRIEF REPORTS

6307 Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis

Sara Pizzamiglio, Chiara Maura Ciniselli, Tiziana Triulzi, Chiara Gargiuli, Loris De Cecco, Evandro de Azambuja, Debora Fumagalli, Christos Sotiriou, Nadia Harbeck, Miguel Izquierdo, Paolo Nuciforo, Jens Huober, Vera Cappelletti, Saverio Cinieri, Martine Piccart, Maria Grazia Daidone, Giancarlo Pruner, Mario Paolo Colombo, Elda Tagliabue, Paolo Verderio, and Serena Di Cosimo

CLINICAL TRIALS: TARGETED THERAPY

6314 Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

E. Gabriela Chiorean, Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia Jalikis, Michael J. Pishvaian, Jordan Berlin, Marcus S. Noel, Jennifer M. Suga, Ignacio Garrido-Laguna, Dana Backlund Cardin, Marc R. Radke, Mai Duong, Shay Bellasea, Andrew M. Lowy, and Howard S. Hochster

6323 The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma

Stephen Opat, Alessandra Tedeschi, Kim Linton, Pamela McKay, Bei Hu, Henry Chan, Jie Jin, Magdalena Sobieraj-Teague, Pier Luigi Zinzani, Morton Coleman, Catherine Thieblemont, Peter Browett, Xiaoyan Ke, Mingyuan Sun, Robert Marcus, Craig A. Portell, Kirit Ardeshta, Fontanet Bijou, Patricia Walker, Eliza A. Hawkes, Sally Mapp, Shir-Jing Ho, Dipti Talaulikar, Ke-Shu Zhou, Melannie Co, Xiaotong Li, Wenxiao Zhou, Massimo Cappellini, Chris Tankersley, Jane Huang, and Judith Trotman

6333 Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous *KIT*/*PDGFRA* Mutations in the Phase III INVICTUS Study

Sebastian Bauer, Michael C. Heinrich, Suzanne George, John R. Zalberg, César Serrano, Hans Gelderblom, Robin L. Jones, Steven Attia, Gina D'Amato, Ping Chi, Peter Reichardt, Julie Meade, Ying Su, Rodrigo Ruiz-Soto, Jean-Yves Blay, Margaret von Mehren, and Patrick Schöffski

TABLE OF CONTENTS

6343 Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas

Jennifer Y. Wo, Jeffrey W. Clark, Christine E. Eyler, Mari Mino-Kenudson, Samuel J. Klempner, Jill N. Allen, Florence K. Keane, Aparna R. Parikh, Eric Roeland, Lorraine C. Drapek, David P. Ryan, Ryan B. Corcoran, Emily Van Seventer, Isobel J. Fetter, Heather A. Shahzade, Melin J. Khandekar, Michael Lanuti, Christopher R. Morse, Rebecca S. Heist, Christine A. Ulysse, Benjamin Christopher, Christian Baglini, Beow Y. Yeap, John T. Mullen, and Theodore S. Hong

See related commentary, p. 6281

6354 Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer

Shannon N. Westin, Marilyne Labrie, Jennifer K. Litton, Aurora Blucher, Yong Fang, Christopher P. Vellano, Joseph R. Marszalek, Ningping Feng, XiaoYan Ma, Allison Creason, Bryan Fellman, Ying Yuan, Sanghoon Lee, Tae-Beom Kim, Jinsong Liu, Anca Chelariu-Raicu, Tsun Hsuan Chen, Nashwa Kabil, Pamela T. Soliman, Michael Frumovitz, Katheleen M. Schmeler, Amir Jazaeri, Karen H. Lu, Rashmi Murthy, Larissa A. Meyer, Charlotte C. Sun, Anil K. Sood, Robert L. Coleman, and Gordon B. Mills

6366 A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation

Florence Atrafi, Oliver Boix, Vivek Subbiah, Jennifer R. Diamond, Sant P. Chawla, Anthony W. Tolcher, Patricia M. LoRusso, Joseph P. Eder, Martin Gutierrez, Kumar Sankhala, Prabhu Rajagopalan, Isabelle Genvresse, Simon Langer, Ron H.J. Mathijssen, Jaap Verweij, Ingmar Bruns, and Martijn P. Lolkema

6376 Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in ¹¹C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer

Henan Zhang, Jacob J. Orme, Feven Abraha, B.J. Stish, Val J. Lowe, Fabrice Lucien, Erik J. Tryggestad, Michael S. Bold, Lance C. Pagliaro, C. Richard Choo, Debra H. Brinkmann, Matthew J. Iott, Brian J. Davis, J. Fernando Quevedo, William S. Harmsen, Brian A. Costello, Geoffrey B. Johnson, Mark A. Nathan, Kenneth R. Olivier, Thomas M. Pisansky, Eugene D. Kwon, Haidong Dong, and Sean S. Park

CLINICAL TRIALS: IMMUNOTHERAPY

6384 Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy

Mingming Zhang, Linghui Zhou, Houli Zhao, Yanlei Zhang, Guoqing Wei, Ruimin Hong, Wenjun Wu, Huijun Xu, Linqin Wang, Fang Ni, Jiazhen Cui, Shuixiu Peng, Chih-Hua Huang, Alex H. Chang, Yongxian Hu, and He Huang

6393 Safety and Antitumor Activity of α -PD-L1 Antibody as Monotherapy or in Combination with α -TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors

Antoine Hollebecque, Hyun C. Chung, Maria J. de Miguel, Antoine Italiano, Jean-Pascal Machiels, Chia-Chi Lin, Neesha C. Dhani, Marc Peeters, Victor Moreno, Wu-Chou Su, Kay Hoong Chow, Violeta R. Galvao, Michelle Carlsen, Danni Yu, Anna M. Szpurka, Yumin Zhao, Shelly L. Schmidt, Leena Gandhi, Xiaojian Xu, and Yung-Jue Bang

6405 Immunization with a Plasmid DNA Vaccine Encoding the N-Terminus of Insulin-like Growth Factor Binding Protein-2 in Advanced Ovarian Cancer Leads to High-level Type I Immune Responses

Denise L. Cecil, John B. Liao, Yushe Dang, Andrew L. Coveler, Angela Kask, Yi Yang, Jennifer S. Childs, Doreen M. Higgins, and Mary L. Disis

6413 Phase II, Randomized Study of Spartalizumab (PDRO01), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Caroline Even, Hung-Ming Wang, Shau-Hsuan Li, Roger K-C Ngan, Arunee Dechaphunkul, Li Zhang, Chia-Jui Yen, Po Chung Chan, Somvilai Chakrabandhu, Brigitte B.Y. Ma, Suebpong Tanasanvimon, Victor H.F. Lee, Pei-Jen Lou, Zujun Li, Alexander I. Spira, Ammar Sukari, Joël Guigay, Steven McCune, Juan Gonzalez-Maffe, Sebastian Szpakowski, Yao Yao, Hongzi Liang, Jennifer Mataraza, Romain Séchaud, Luigi Manenti, and Darren W-T. Lim

6424 Phase II Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and Unresectable Soft-Tissue Sarcoma

Michael B. Livingston, Megan H. Jagosky, Myra M. Robinson, William A. Ahrens, Jennifer H. Benbow, Carol J. Farhangfar, David M. Foureau, Deirdre M. Maxwell, Emily A. Baldrige, Xhevahire Begic, James T. Symanowski, Nury M. Steuerwald, Colin J. Anderson, Joshua C. Patt, Jeffrey S. Kneisl, and Edward S. Kim

TABLE OF CONTENTS

PRECISION MEDICINE AND IMAGING

- 6432** **Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in *BRAF*-Mutated Multiple Myeloma**
Johannes M. Waldschmidt, Jake A. Kloeber, Praveen Anand, Julia Frede, Antonis Kokkalis, Valeriya Dimitrova, Sayalee Potdar, Monica S. Nair, Tushara Vijaykumar, Nam Gyu Im, Amy Guillaumet-Adkins, Nitish Chopra, Hannah Stuart, Lillian Budano, Noori Sotudeh, Guangwu Guo, Clemens Grassberger, Andrew J. Yee, Jacob P. Laubach, Paul G. Richardson, Kenneth C. Anderson, Noopur S. Raje, Birgit Knoechel, and Jens G. Lohr
- 6445** **Whole-body PET Imaging of T-cell Response to Glioblastoma**
Tomomi W. Nobashi, Aaron T. Mayer, Zunyu Xiao, Carmel T. Chan, Aisling M. Chaney, Michelle L. James, and Sanjiv S. Gambhir
- 6457** **Diagnostic Accuracy of FEC-PET/CT, FDG-PET/CT, and Diffusion-Weighted MRI in Detection of Nodal Metastases in Surgically Treated Endometrial and Cervical Carcinoma**
Andrea G. Rockall, Tara D. Barwick, William Wilson, Naveena Singh, Nishat Bharwani, Aslam Sohaib, Marielle Nobbenhuis, Victoria Warbey, Marc Miquel, Dow-Mu Koh, Katja N. De Paepe, Pierre Martin-Hirsch, Sadaf Ghaem-Maghani, Christina Fotopoulou, Helen Stringfellow, Sudha Sundar, Ranjit Manchanda, Anju Sahdev, Allan Hackshaw, and Gary J. Cook; the MAPPING Study Group
- 6467** **A Clinical PET Imaging Tracer ($[^{18}\text{F}]\text{DASA-23}$) to Monitor Pyruvate Kinase M2-Induced Glycolytic Reprogramming in Glioblastoma**
Corinne Beinat, Chirag B. Patel, Tom Haywood, Surya Murty, Lewis Naya, Jessa B. Castillo, Samantha T. Reyes, Megan Phillips, Pablo Buccino, Bin Shen, Jun Hyung Park, Mary Ellen I. Koran, Israt S. Alam, Michelle L. James, Dawn Holley, Kim Halbert, Harsh Gandhi, Joy Q. He, Monica Granucci, Eli Johnson, Daniel Dan Liu, Nobuko Uchida, Rahul Sinha, Pauline Chu, Donald E. Born, Geoffrey I. Warnock, Irving Weissman, Melanie Hayden-Gephart, Mehdi Khalighi, Tarik F. Massoud, Andrei Iagaru, Guido Davidzon, Reena Thomas, Seema Nagpal, Lawrence D. Recht, and Sanjiv Sam Gambhir

- 6479** **Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma**
Bachisio Ziccheddu, Matteo C. Da Vià, Marta Lionetti, Akihiro Maeda, Silvia Morlupi, Matteo Dugo, Katia Todoerti, Stefania Oliva, Mattia D'Agostino, Paolo Corradini, Ola Landgren, Francesco Iorio, Loredana Pettine, Alessandra Pompa, Martina Manzoni, Luca Baldini, Antonino Neri, Francesco Maura, and Niccolò Bolli
- 6491** **Prognostic Relevance of Pancreatic Adenocarcinoma Whole-Tumor Transcriptomic Subtypes and Components**
Shulin Zhao, Rémy Nicolle, Jérémy Augustin, Magali Svrcek, Louis de Mestier, Delphine Le Corre, Daniel Pietrasz, Olivier Caliez, Jérôme Cros, Pierre Laurent-Puig, and Jean-Baptiste Bachet

TRANSLATIONAL CANCER MECHANISMS AND THERAPY

- 6500** **The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms *In Vitro* and in a First-In-Human Phase I Clinical Trial**
Hagen Schwenzler, Erica De Zan, Mustafa Elshani, Ruud van Stiphout, Mary Kudsy, Josephine Morris, Valentina Ferrari, In Hwa Um, James Chettle, Farasat Kazmi, Leticia Campo, Alistair Easton, Sebastian Nijman, Michaela Serpi, Stefan Symeonides, Ruth Plummer, David J. Harrison, Gareth Bond, and Sarah P. Blagden
- 6514** **Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma**
Lijie Zhai, April Bell, Erik Ladomersky, Kristen L. Lauing, Lakshmi Bollu, Brenda Nguyen, Matthew Genet, Miri Kim, Peiwen Chen, Xinlei Mi, Jennifer D. Wu, Matthew J. Schipma, Brian Wray, John Griffiths, Richard D. Unwin, Simon J. Clark, Rajesh Acharya, Riyue Bao, Craig Horbinski, Rimas V. Lukas, Gary E. Schiltz, and Derek A. Wainwright
- 6529** **Spatially Distinct Reprogramming of the Tumor Microenvironment Based On Tumor Invasion in Diffuse-Type Gastric Cancers**
Hye Young Jeong, In-Hye Ham, Sung Hak Lee, Daeun Ryu, Sang-Yong Son, Sang-Uk Han, Tae-Min Kim, and Hoon Hur
See related commentary, p. 6284
- 6543** **Fresh Tissue Multi-omics Profiling Reveals Immune Classification and Suggests Immunotherapy Candidates for Conventional Chondrosarcoma**
Binghao Li, Guoqi Li, Xiaobo Yan, Dan Zhu, Patrick P. Lin, Zenan Wang, Hao Qu, Xuexin He, Yanbiao Fu, Xiuliang Zhu, Peng Lin, Jiangnan Zhang, Xiaoya Li, Hui Dai, Huabiao Chen, Mark C. Poznansky, Nong Lin, and Zhaoming Ye

TABLE OF CONTENTS

- 6559 Ovarian Cancer–Specific *BRCA*-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial**
Philip C. Schouten, Lisa Richters, Daniel J. Vis, Stefan Kommos, Ewald van Dijk, Corinna Ernst, Roelof J.C. Kluin, Frederik Marmé, Esther H. Lips, Sandra Schmidt, Esther Scheerman, Katharina Prieske, Carolien H.M. van Deurzen, Alexander Burges, Patricia C. Ewing-Graham, Dimo Dietrich, Agnes Jager, Nikolaus de Gregorio, Jan Hauke, Andreas du Bois, Petra M. Nederlof, Lodewyk F. Wessels, Eric Hahnen, Philipp Harter, Sabine C. Linn, and Rita K. Schmutzler
- 6570 Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials**
Karama Asleh, Dongsheng Tu, Dongxia Gao, Vivien Bramwell, Mark N. Levine, Kathleen I. Pritchard, Lois E. Shepherd, and Torsten O. Nielsen
- 6580 The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma**
Shwetha H. Manjunath, Adam D. Cohen, Simon F. Lacey, Megan M. Davis, Alfred L. Garfall, J. Joseph Melenhorst, Russell Maxwell, W. Tristram Arscott, Amit Maity, Joshua A. Jones, John P. Plataras, Edward A. Stadtmauer, Bruce L. Levine, Carl H. June, Michael C. Milone, and Ima Paydar
- 6591 Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma**
Marcelo Lima Ribeiro, Diana Reyes-Garau, Meritxell Vinyoles, Núria Profitós Pelejà, Juliana Carvalho Santos, Marc Armengol, Miranda Fernández-Serrano, Alicia Sedó Mor, Joan J. Bech-Serra, Pedro Blecua, Eva Musulen, Carolina De La Torre, Hari Miskin, Manel Esteller, Francesc Bosch, Pablo Menéndez, Emmanuel Normant, and Gaël Roué
- 6602 Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma**
Elham Aida Farshadi, Jiang Chang, Bharath Sampadi, Michail Doukas, Freek Van 't Land, Fleur van der Sijde, Eveline E. Vietsch, Joris Pothof, Bas Groot Koerkamp, and Casper H.J. van Eijck


LETTERS TO THE EDITOR

- 6613 Plasma-only ctDNA-Guided MRD Detection in Patients with CRC—Letter**
Thomas Reinert, Tenna V. Henriksen, Alexey Aleshin, Bernhard Zimmermann, and Claus Lindbjerg Andersen
- 6614 Plasma-only ctDNA-Guided MRD Detection in Patients with CRC—Response**
Aparna R. Parikh and Ryan B. Corcoran

ABOUT THE COVER

The cover shows a section of a surgical specimen from a patient with diffuse-type gastric cancer. Masson's trichrome staining shows that accumulation of stromal collagen (*sky blue*) in the deep invasive portion of the primary tumor is more profuse when compared with the superficial portion. For details, see the article by Jeong and colleagues on page 6529 of this issue.

doi: 10.1158/1078-0432.CCR-27-23-CVR



Clinical Cancer Research

27 (23)

Clin Cancer Res 2021;27:6279-6615.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/27/23>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/27/23>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.